Lorukafusp alfa

DB15443Investigational

Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).

Mechanism: Pharmacologically active on GD2 disialoganglioside
Curator reviewed
Also known as: EMD 273063 · HU14.18-IL2

Resolves to

Compound

UNIIPL21OR4LXECAS2131168-99-3

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Lorukafusp alfa, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account